Fetroja (Cefiderocol Sulfate Tosylate) Patent Expiration, LOE Window & CMS Spending

Fetroja (Cefiderocol Sulfate Tosylate) by Shionogi: FDA Orange Book core substance LOE 2035-09-03, 0 AB generics, $11.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorShionogi
FDA Application & PathwayN209445 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-09-03
Last Listed Patent or Exclusivity Date2035-09-03
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$11.2M
2024 Medicare Part D Spend$6.9M
2024 Medicaid Spend$4.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.0% 2-yr change)